EP1451308A4 - Therapeutic use of aziridino compounds - Google Patents

Therapeutic use of aziridino compounds

Info

Publication number
EP1451308A4
EP1451308A4 EP02806003A EP02806003A EP1451308A4 EP 1451308 A4 EP1451308 A4 EP 1451308A4 EP 02806003 A EP02806003 A EP 02806003A EP 02806003 A EP02806003 A EP 02806003A EP 1451308 A4 EP1451308 A4 EP 1451308A4
Authority
EP
European Patent Office
Prior art keywords
therapeutic use
aziridino compounds
aziridino
compounds
therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02806003A
Other languages
German (de)
French (fr)
Other versions
EP1451308A2 (en
Inventor
John Chapman
Bernadette Alford
Andrei A Purmal
Boris Zavizion
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
VI Technologies Inc
Original Assignee
VI Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2001/049956 external-priority patent/WO2002055095A2/en
Application filed by VI Technologies Inc filed Critical VI Technologies Inc
Publication of EP1451308A2 publication Critical patent/EP1451308A2/en
Publication of EP1451308A4 publication Critical patent/EP1451308A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/396—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having three-membered rings, e.g. aziridine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP02806003A 2001-11-06 2002-11-05 Therapeutic use of aziridino compounds Withdrawn EP1451308A4 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
WOPCT/US01/49956 2001-11-06
PCT/US2001/049956 WO2002055095A2 (en) 2000-11-06 2001-11-06 Use of aziridino-compounds in the treatment of immune dysfunctions
US36564802P 2002-03-18 2002-03-18
US365648P 2002-03-18
US37918802P 2002-05-09 2002-05-09
US379188P 2002-05-09
PCT/US2002/035501 WO2003066806A2 (en) 2001-11-06 2002-11-05 Therapeutic use of aziridino compounds

Publications (2)

Publication Number Publication Date
EP1451308A2 EP1451308A2 (en) 2004-09-01
EP1451308A4 true EP1451308A4 (en) 2004-11-17

Family

ID=27738963

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02806003A Withdrawn EP1451308A4 (en) 2001-11-06 2002-11-05 Therapeutic use of aziridino compounds

Country Status (5)

Country Link
EP (1) EP1451308A4 (en)
JP (1) JP2005517023A (en)
AU (1) AU2002366446A1 (en)
CA (1) CA2466251A1 (en)
WO (1) WO2003066806A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040053208A1 (en) * 1995-08-29 2004-03-18 V. I. TECHNOLOGIES, Inc. Methods to selectively inactivate parasites in biological compositions
US9040507B2 (en) 2008-06-02 2015-05-26 Novelmed Therapeutics, Inc. Method for treating inflammatory conditions

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0419890A2 (en) * 1989-09-29 1991-04-03 American Cyanamid Company Stable pharmaceutical formulations for antineoplastic compounds having more than one ethyleneimine group, and method
WO1997007674A1 (en) * 1995-08-29 1997-03-06 Pentose Pharmaceuticals, Inc. Methods and compositions for the selective modification of nucleic acids
WO2002055095A2 (en) * 2000-11-06 2002-07-18 Vi Technologies Inc Use of aziridino-compounds in the treatment of immune dysfunctions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136586A (en) * 1995-08-29 2000-10-24 Vi Technologies, Inc. Methods for the selective modification of viral nucleic acids
US6093564A (en) * 1997-10-03 2000-07-25 V.I. Technologies, Inc. Methods and compositions for the selective modification of nucleic acids

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0419890A2 (en) * 1989-09-29 1991-04-03 American Cyanamid Company Stable pharmaceutical formulations for antineoplastic compounds having more than one ethyleneimine group, and method
WO1997007674A1 (en) * 1995-08-29 1997-03-06 Pentose Pharmaceuticals, Inc. Methods and compositions for the selective modification of nucleic acids
WO2002055095A2 (en) * 2000-11-06 2002-07-18 Vi Technologies Inc Use of aziridino-compounds in the treatment of immune dysfunctions

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CHAPMAN JOHN: "Progress in improving the pathogen safety of red cell concentrates.", VOX SANGUINIS, vol. 78, no. Suppl. 2, July 2000 (2000-07-01), pages 203 - 204, XP008004989, ISSN: 0042-9007 *
FAST-L: "Treatment of human leukocytes with inactine-TM results in loss of function and induction of apoptosis", BLOOD, vol. 96, no. 11, 16 November 2000 (2000-11-16), pages 61A, XP001073993 *
KASERMANN FABIAN ET AL: "Virus inactivation and protein modifications by ethyleneimines", ANTIVIRAL RESEARCH, vol. 52, no. 1, October 2001 (2001-10-01), pages 33 - 41, XP002296019, ISSN: 0166-3542 *
PURMAL ANDREI ET AL: "Process for the preparation of pathogen-inactivated RBC concentrates by using PEN110 chemistry: Preclinical studies", TRANSFUSION (BETHESDA), vol. 42, no. 2, February 2002 (2002-02-01), pages 139 - 145, XP002296020, ISSN: 0041-1132 *
RICHTER H I ET AL: "[Extracorporeal photopheresis in therapy-refractory disseminated discoid lupus erythematosus]", DER HAUTARZT;ZEITSCHRIFT FUR DERMATOLOGIE, VENEROLOGIE, UND VERWANDTE GEBIETE. GERMANY JUN 1998, vol. 49, no. 6, June 1998 (1998-06-01), pages 487 - 491, XP002203620, ISSN: 0017-8470 *

Also Published As

Publication number Publication date
AU2002366446A1 (en) 2003-09-02
EP1451308A2 (en) 2004-09-01
WO2003066806A2 (en) 2003-08-14
WO2003066806A3 (en) 2003-12-24
JP2005517023A (en) 2005-06-09
CA2466251A1 (en) 2003-08-14

Similar Documents

Publication Publication Date Title
EP1416884A4 (en) Delivery of therapeutic capable agents
IL196301A0 (en) Medicament for the treatment of hapatitis c
IL156595A0 (en) Therapeutic heterocyclic compounds
GB0013378D0 (en) Use of therapeutic benzamide derivatives
GB0305150D0 (en) Use of therapeutic compounds
GB0108930D0 (en) Therapeutic agents
HUP0500734A3 (en) Use of 2-alkoxyphenyl-substituted imidazotriazinones
GB0119025D0 (en) Compounds and their therapeutic use
HK1070561A1 (en) Use of specific dose of fandaparinux sodium for the treatment of acs
EP1451308A4 (en) Therapeutic use of aziridino compounds
GB2376943B (en) Compounds and their therapeutic use
GB0108982D0 (en) Therapeutic agents
GB0112237D0 (en) Compounds and their therapeutic use
GB0128122D0 (en) Therapeutic use
GB0123991D0 (en) New therapeutic use
EP1377289A4 (en) Heterocyclic compounds for therapeutic use
GB0024517D0 (en) Use of medicaments
GB0108973D0 (en) Therapeutic agents
GB0130736D0 (en) Compounds and their therapeutic use
GB0128512D0 (en) Compounds and their therapeutic use
GB0104615D0 (en) Treatment of technetium
GB0105097D0 (en) Treatment of technetium
GB0118627D0 (en) Use of compounds in therapy
GB0106802D0 (en) Therapeutic use
GB0128126D0 (en) Therapeutic use

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040524

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61P 35/00 B

Ipc: 7A 61P 37/00 B

Ipc: 7A 61K 31/395 B

Ipc: 7A 61K 35/14 A

A4 Supplementary search report drawn up and despatched

Effective date: 20041004

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20050601